Sell high, buy low

PDL BioPharma Inc. may not have gotten what it wanted from its 2005 purchase of ESP Pharma Inc. for $610 million, but ESP's management has done more than well. Last week, ESP's founders came back around to buy some of the same products and one of its original candidates, now at bargain basement prices.

PDL bought ESP for its $90 million 2004 sales stream, which included Cardene IV nicardipine and Busulfex

Read the full 719 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers